These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 20945363)

  • 1. Underutilization of therapy for hepatocellular carcinoma in the medicare population.
    Shah SA; Smith JK; Li Y; Ng SC; Carroll JE; Tseng JF
    Cancer; 2011 Mar; 117(5):1019-26. PubMed ID: 20945363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
    El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
    J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The burden of illness associated with hepatocellular carcinoma in the United States.
    Lang K; Danchenko N; Gondek K; Shah S; Thompson D
    J Hepatol; 2009 Jan; 50(1):89-99. PubMed ID: 18977551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study.
    Kokabi N; Duszak R; Xing M; Howard DH; Applegate KE; Camacho JC; Kim HS
    Future Oncol; 2017 Oct; 13(23):2021-2033. PubMed ID: 28984155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kentucky hepatoma: epidemiologic variant or same problem in a different region?
    Martin RC; Loehle J; Scoggins CR; McMasters KM
    Arch Surg; 2007 May; 142(5):431-6; discussion 436-7. PubMed ID: 17515484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma - United States, 2001-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(17):517-20. PubMed ID: 20448528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
    Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
    Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality and hospital utilization for hepatocellular carcinoma in the United States.
    Kim WR; Gores GJ; Benson JT; Therneau TM; Melton LJ
    Gastroenterology; 2005 Aug; 129(2):486-93. PubMed ID: 16083705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in the Netherlands incidence, treatment and survival patterns.
    Verhoef C; Visser O; de Man RA; de Wilt JH; IJzermans JN; Janssen-Heijnen ML
    Eur J Cancer; 2004 Jul; 40(10):1530-8. PubMed ID: 15196537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising incidence and demographics of hepatocellular carcinoma in the USA: what does it mean?
    Shaw JJ; Shah SA
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):365-70. PubMed ID: 21651354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
    Stuart KE; Anand AJ; Jenkins RL
    Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based risk factors and resource utilization for HCC: US perspective.
    Sanyal A; Poklepovic A; Moyneur E; Barghout V
    Curr Med Res Opin; 2010 Sep; 26(9):2183-91. PubMed ID: 20666689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of hepatologists to extend survival of hepatocellular carcinoma patients with cirrhosis: a comparison with non-hepatologists.
    Dohmen K; Shirahama M; Shigematsu H; Irie K; Ishibashi H
    Hepatogastroenterology; 2004; 51(56):564-9. PubMed ID: 15086203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States.
    El-Serag HB; Mason AC; Key C
    Hepatology; 2001 Jan; 33(1):62-5. PubMed ID: 11124821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma in the United States. Lessons from a population-based study in Medicare recipients.
    Varela M; Bruix J
    J Hepatol; 2006 Jan; 44(1):8-10. PubMed ID: 16297492
    [No Abstract]   [Full Text] [Related]  

  • 16. Trends in the use of radical prostatectomy for treatment of prostate cancer.
    Ellison LM; Heaney JA; Birkmeyer JD
    Eff Clin Pract; 1999; 2(5):228-33. PubMed ID: 10623055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hepatocellular carcinoma].
    Greten TF; Blum HE; Manns MP; Geissler M
    Z Gastroenterol; 2006 Jan; 44(1):43-9. PubMed ID: 16397839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocellular cancer care: cost is important but only one factor of disease burden.
    Kanwal F; El-Serag HB
    J Hepatol; 2009 Jan; 50(1):10-2. PubMed ID: 19019482
    [No Abstract]   [Full Text] [Related]  

  • 19. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study.
    El-Serag HB; Davila JA
    Hepatology; 2004 Mar; 39(3):798-803. PubMed ID: 14999699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States.
    Marrero JA; Fontana RJ; Su GL; Conjeevaram HS; Emick DM; Lok AS
    Hepatology; 2002 Dec; 36(6):1349-54. PubMed ID: 12447858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.